questionText: To ask the Secretary of State for Health and Social Care, for what reason NHS England has not approved abiraterone for use in high-risk, non-metastatic prostate cancer.
answerText: Abiraterone is licensed by the Medicines and Healthcare products Regulatory Agency for use in the treatment of high-risk hormone-sensitive metastatic prostate cancer. The National Institute for Health and Care Excellence (NICE) has published final draft g...
heading: Abiraterone